Table 4. Hematologic and nonhematologic adverse eventsa.
| Adverse event preferred term, n (%) | Carfilzomib (n=157) | Control (n=153) | ||
|---|---|---|---|---|
| All grades | Grade ⩾3 | All grades | Grade ⩾3 | |
| Any adverse event | 154 (98) | 118 (75) | 143 (94) | 109 (71) |
| Hematologic | ||||
| Anemia | 88 (56) | 40 (25) | 75 (49) | 47 (31) |
| Thrombocytopenia | 59 (38) | 38 (24) | 46 (30) | 34 (22) |
| Neutropenia | 23 (15) | 12 (8) | 26 (17) | 19 (12) |
| Leukopenia | 10 (6) | 5 (3) | 15 (10) | 11 (7) |
| Nonhematologic | ||||
| Nausea | 32 (20) | 2 (1) | 14 (9) | 2 (1) |
| Pyrexia | 44 (28) | 5 (3) | 30 (20) | 0 (0) |
| Pneumonia | 12 (8) | 10 (6) | 20 (13) | 19 (12) |
| Decreased platelet count | 12 (8) | 5 (3) | 12 (8) | 7 (5) |
| Hypercalcemia | 17 (11) | 6 (4) | 10 (7) | 7 (5) |
| Acute renal failure | 15 (10) | 12 (8) | 6 (4) | 5 (3) |
| Renal failure | 10 (6) | 8 (5) | 3 (2) | 2 (1) |
| Other adverse events of interest | ||||
| Chest pain | 5 (3) | 0 (0) | 9 (6) | 1 (1) |
| Increased blood creatinine | 13 (8) | 3 (2) | 10 (7) | 1 (1) |
| Decreased creatinine renal clearance | 9 (6) | 1 (1) | 4 (3) | 3 (2) |
| Renal impairment | 11 (7) | 6 (4) | 5 (3) | 1 (1) |
| Dyspnea | 23 (15) | 2 (1) | 13 (9) | 0 (0) |
| Cough | 19 (12) | 1 (1) | 10 (7) | 1 (1) |
| Hypertension | 23 (15) | 5 (3) | 9 (6) | 0 (0) |
| Cardiac failure | 7 (5) | 3 (2) | 1 (1) | 1 (1) |
| Peripheral neuropathy | 7 (5) | 1 (1) | 6 (4) | 0 (0) |
a
Adverse events of any grade reported in ⩾20% of patients in either treatment arm and grade ⩾3 adverse events reported in ⩾5% of patients in either treatment arm are listed. Adverse events of clinical interest are also listed.